Highly functionalized 2-oxopiperazine-based peptidomimetics: An approach to PAR1 antagonists

European Journal of Medicinal Chemistry

Volumn 70, Issue , 2013, Pages 199-224

  Valdivielso, Ángel M ^a   Ventosa Andrés, Pilar ^a   Tato, Francisco ^a   Fernández Ibañez, M Ángeles ^a   Pappos, Ioannis ^b   Tsopanoglou, Nikos E ^b   García López, M Teresa ^a   Gutiérrez Rodríguez, Marta ^a   Herranz, Rosario ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

2 Oxopiperazines; Cytotoxicity; PAR1 antagonists; Peptidomimetics; Platelet antiaggregant activity; Amino nitriles

Indexed keywords

4 BENZYL 5 1 (TERT BUTOXYCARBONYL)AMINO 2 [1 (TERT BUTOXYCARBONYL) INDOL 3 YL]ETHYL 3 [3 [2 [(2,2,4,6,7 PENTAMETHYL 2,3 DIHYDROBENZOFURAN 5 YL)SULFONYL] GUANIDINO]PROPYL] 2 OXOPIPERAZINE; 4 BENZYL 5 1 (TERT BUTOXYCARBONYL)AMINO 2 [1 (TERT BUTOXYCARBONYL)INDOL 3 YL]ETHYL 3 [4 [(TERT BUTOXYCARBONYL)AMINO]BUTYL] 2 OXOPIPERAZINE; 5 1 (TERT BUTOXYCARBONYL)AMINO 2 [1 (TERT BUTOXYCARBONYL) INDOL 3 YL]ETHYL 4 (TERT BUTOXYCARBONYL)METHYL 3 [3 [2 [(2,2,4,6,7 PENTAMETHYL 2,3 DIHYDROBENZOFURAN 5 YL)SULFONYL]GUANIDINO]PROPYL] 2 OXOPIPERAZINE; CARBON; CYTOTOXIC AGENT; DOXORUBICIN; NITROGEN; PEPTIDOMIMETIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 1; RWJ 58259; SOLVENT; THIOUREA; UNCLASSIFIED DRUG; UREA; UREA DERIVATIVE; VORAPAXAR;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST PROSTHESIS; CANCER CELL CULTURE; CONFORMATION; DATA BASE; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; THROMBOCYTE AGGREGATION; TOOTH IMPLANT;

2-OXOPIPERAZINES; CYTOTOXICITY; PAR1 ANTAGONISTS; PEPTIDOMIMETICS; PLATELET ANTIAGGREGANT ACTIVITY; Α-AMINO NITRILES;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HT29 CELLS; HUMANS; MOLECULAR CONFORMATION; PEPTIDOMIMETICS; PIPERAZINES; PLATELET AGGREGATION; RECEPTOR, PAR-1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84886068500     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.09.058     Document Type: Article

References (60)

1. S.R. Macfarlane, M.J. Seatter, T. Kanke, G.D. Hunter, and R. Plevin Proteinase-activated receptors Pharmacol. Rev. 53 2001 245 282 (Pubitemid 32476117)
2. L. Martorell, J. Martínez-González, C. Rodríguez, M. Gentile, O. Calvayrac, and L. Badimon Thrombin and protease-activated receptors (PARs) in atherothrombosis Thromb. Haemost. 99 2008 305 315 (Pubitemid 351230960)
3. R. Shah Protease-activated receptors in cardiovascular health and diseases Am. Heart J. 157 2009 253 262
4. R. Ramachandran, F. Noorbakhsh, K. Defea, and M.D. Hollenberg Targeting proteinase-activated receptors: therapeutic potential and challenges Nat. Rev. Drug Discov. 11 2012 69 86
5. V.S. Ossovskaya, and N.W. Bunnett Protease-activated receptors: contribution to physiology and disease Physiol. Rev. 84 2004 579 621 (Pubitemid 38365493)
6. E. Sokolova, and G. Reiser Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases Thromb. Haemost. 100 2008 576 581
7. W. Luo, Y. Wang, and G. Reiser The role of thrombin and thrombin receptors in the brain M.E. Maragoudakis, N.E. Tsopanoglou, Thrombin: Physiology and Disease 2009 Springer New York 133 159
8. Y. Hashimotodani, T. Ohno-Shosaku, M. Yamazaki, K. Sakimura, and M. Kano Neuronal protease-activated receptor 1 drives synaptic retrograde signaling mediated by the endocannabinoid 2-arachidonoylglycerol J. Neurosci. 31 2011 3104 3109
9. A.G. Almonte, L.H. Qadri, F.A. Sultan, J.A. Watson, D.J. Mount, G. Rumbaugh, and J.D. Sweatt Protease-activated receptor-1 modulates hippocampal memory formation and synaptic plasticity J. Neurochem. 124 2013 109 122
10. N. Maggio, C. Cavaliere, M. Papa, I. Blatt, J. Chapman, and M. Segal Thrombin regulation of synaptic transmission: implications for seizure onset Neurobiol. Dis. 50 2013 171 178
11. M. Steinhoff, J. Buddenkotte, V. Shpacovitch, A. Rattenholl, C. Moormann, N. Vergnolle, T.A. Luger, and M.D. Hollenberg Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response Endocr. Rev. 26 2005 1 43 (Pubitemid 40209385)
12. R. Ramachandran, M. El-Daly, M. Saifeddine, and M.D. Hollenberg Thrombin: to PAR or not to PAR, and the regulation of inflammation M.E. Maragoudakis, N.E. Tsopanoglou, Thrombin: Physiology and Disease 2009 Springer New York 19 46
13. P. Arora, T.K. Ricks, and J. Trejo Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer J. Cell Sci. 120 2007 921 928 (Pubitemid 46638507)
14. E. Camerer Protease signaling in tumor progression Thromb. Res. 120 Suppl. 2 2007 S75 S81
15. K.S. Borensztajn, and C.A. Spek Protease-activated receptors, apoptosis and tumor growth Pathophysiol. Haemost. Thromb. 36 2008 137 147
16. B. Kobrinsky, and S. Karpatkin The role of thrombin in tumor biology M.E. Maragoudakis, N.E. Tsopanoglou, Thrombin: Physiology and Disease 2009 Springer New York 161 172
17. C.S.B. Veiga, T.C. Carneiro-Lobo, C.J.B.P. Coelho, S.M.F. Carvalho, R.C. Maia, F.C. Vasconcelos, E. Abdelhay, A.L. Mencalha, A.F. Ferreira, F.A. Castro, and R.Q. Monteiro Increased expression of protease-activated receptor 1 (PAR-1) in human leukemias Blood Cells Mol. Dis. 46 2011 230 234
18. Z. Salah, B. Uziely, M. Jaber, M. Maoz, I. Cohen, T. Hamburger, B. Maly, T. Peretz, and R. Bar-Shavit Regulation of human protease-activated receptor 1 (hPar1) gene expression in breast cancer by estrogen FASEB J. 26 2012 2031 2042
19. M.T. García-López, M. Gutiérrez-Rodríguez, and R. Herranz Thrombin-activated receptors: promising targets for cancer therapy? Curr. Med. Chem. 17 2010 109 128
20. C. Chen, B.E. Maryanoff, and P. Andrade-Gordon Thrombin receptor modulators: medicinal chemistry, biological evaluation, and clinical applications M.E. Maragoudakis, N.E. Tsopanoglou, Thrombin: Physiology and Disease 2009 Springer New York 205 236
21. C. Tellez, and M. Bar-Eli Role and regulation of the thrombin receptor (PAR-1) in human melanoma Oncogene 22 2003 3130 3137 (Pubitemid 36713765)
22. S. Granovsky-Grisaru, S. Zaidoun, D. Grisaru, Y. Yekel, D. Prus, U. Beller, and R. Bar-Shavit The pattern of protease activated receptor 1 (PAR1) expression in endometrial carcinoma Gynecol. Oncol. 103 2006 802 806 (Pubitemid 44821301)
23. X. Zhang, W. Wang, L.D. True, R.L. Vessella, and T.K. Takayama Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis Prostate 69 2009 727 736
24. C. Rudroff, S. Seibold, R. Kaufmann, C.C. Zetina, K. Reise, U. Schafer, A. Schneider, M. Brockmann, J. Scheele, and E.A. Neugebauer Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro Clin. Exp. Metastasis 19 2002 181 189 (Pubitemid 34264089)
25. S. Grisaru-Granovsky, Z. Salah, M. Maoz, D. Pruss, U. Beller, and R. Bar-Shavit Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples Int. J. Cancer 113 2005 372 378 (Pubitemid 40038703)
26. D. Darmoul, V. Gratio, H. Devaud, T. Lehy, and M. Laburthe Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells Am. J. Pathol. 162 2003 1503 1513 (Pubitemid 36512832)
27. P. Ghio, S. Cappia, G. Selvaggi, S. Novello, P. Lausi, G. Zecchina, M. Papotti, P. Borasio, and G.V. Scagliotti Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer Clin. Lung Cancer 7 2006 395 400 (Pubitemid 44043549)
28. X. Zhang, J.L. Hunt, D.P. Landsittel, S. Muller, K. Adler-Storthz, R.L. Ferris, D.M. Shin, and Z.G. Chen Correlation of protease-activated receptor-1 with differentiation markers in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis Clin. Cancer Res. 10 2004 8451 8459 (Pubitemid 40053409)
29. H.C. Zhang, C.K. Derian, P. Andrade-Gordon, W.J. Hoekstra, D.F. McComsey, K.B. White, B.L. Poulter, M.F. Addo, W.M. Cheung, B.P. Damiano, D. Oksenberg, E.E. Reynolds, A. Pandey, R.M. Scarborough, and B.E. Maryanoff Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates J. Med. Chem. 44 2001 1021 1024 (Pubitemid 32852127)
30. S. Chackalamannil, Y. Xia, W.J. Greenlee, M. Clasby, D. Doller, H. Tsai, T. Asberom, M. Czarniecki, H.S. Ahn, G. Boykow, C. Foster, J. Agans-Fantuzzi, M. Bryant, J. Lau, and M. Chintala Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents J. Med. Chem. 48 2005 5884 5887 (Pubitemid 41324598)
31. S. Chackalamannil, Y. Wang, W.J. Greenlee, Z. Hu, Y. Xia, H.S. Ahn, G. Boykow, Y. Hsieh, J. Palamanda, J. Agans-Fantuzzi, S. Kurowski, M. Graziano, and M. Chintala Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity J. Med. Chem. 51 2008 3061 3064 (Pubitemid 351821864)
32. Y. Shinohara, S. Goto, M. Doi, and P. Jensen Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke J. Stroke Cerebrovasc. Dis. 21 2012 318 324
33. P. Tricoci, Z. Huang, C. Held, D.J. Moliterno, P.W. Armstrong, F. Van de Werf, H.D. White, P.E. Aylward, L. Wallentin, E. Chen, Y. Lokhnygina, J. Pei, S. Leonardi, T.L. Rorick, A.M. Kilian, L.H. Jennings, G. Ambrosio, C. Bode, A. Cequier, J.H. Cornel, R. Diaz, A. Erkan, K. Huber, M.P. Hudson, L. Jiang, J.W. Jukema, B.S. Lewis, A.M. Lincoff, G. Montalescot, J.C. Nicolau, H. Ogawa, M. Pfisterer, J.C. Prieto, W. Ruzyllo, P.R. Sinnaeve, R.F. Storey, M. Valgimigli, D.J. Whellan, P. Widimsky, J. Strony, R.A. Harrington, and K.W. Mahaffey Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N. Engl. J. Med. 366 2012 20 33
34. S. Goto, and V. Serebruany Vorapaxar: PAR1 receptor antagonist, antiplatelet therapy Drugs Fut. 36 2011 101 113
35. T.K. Vu, D.T. Hung, V.I. Wheaton, and S.R. Coughlin Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation Cell 64 1991 1057 1068 (Pubitemid 121001193)
36. B.D. Blackhart, L. Ruslim-Litrus, C.C. Lu, V.L. Alves, W. Teng, R.M. Scarborough, E.E. Reynolds, and D. Oksenberg Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide Mol. Pharmacol. 58 2000 1178 1187
37. T.K. Vu, V.I. Wheaton, D.T. Hung, I. Charo, and S.R. Coughlin Domains specifying thrombin-receptor interaction Nature 353 1991 674 677 (Pubitemid 21912589)
38. Y.M. Ayala, A.M. Cantwell, T. Rose, L.A. Bush, D. Arosio, and E. Di Cera Molecular mapping of thrombin-receptor interactions Proteins 45 2001 107 116 (Pubitemid 32896635)
39. M.T. Nieman, and A.H. Schmaier Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site Biochemistry 46 2007 8603 8610 (Pubitemid 47106111)
40. S.L. Jacques, M. LeMasurier, P.J. Sheridan, S.K. Seeley, and A. Kuliopulos Substrate-assisted catalysis of the PAR1 thrombin receptor. Enhancement of macromolecular association and cleavage J. Biol. Chem. 275 2000 40671 44068
41. T. Myles, B.F. Le Bonniec, and S.R. Stone The dual role of thrombin's anion-binding exosite-I in the recognition and cleavage of the protease-activated receptor 1 Eur. J. Biochem. 268 2001 70 77 (Pubitemid 32052249)
42. W.F. Bahou, J.L. Kutok, A. Wong, C.L. Potter, and B.S. Coller Identification of a novel thrombin receptor sequence required for activation-dependent responses Blood 84 1994 4195 4202 (Pubitemid 24371922)
43. T. Nanevicz, M. Ishii, L. Wang, M. Chen, J. Chen, C.W. Turck, F.E. Cohen, and S.R. Coughlin Mechanisms of thrombin receptor agonist specificity. Chimeric receptors and complementary mutations identify an agonist recognition site J. Biol. Chem. 270 1995 21619 21625
44. P.S. Gandhi, Z. Chen, F.S. Mathews, and E. Di Cera Structural identification of the pathway of long-range communication in an allosteric enzyme Proc. Natl. Acad. Sci. U. S. A. 105 2008 1832 1837 (Pubitemid 351439425)
45. P.S. Gandhi, Z. Chen, and E. Di Cera Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1 J. Biol. Chem. 285 2010 15393 15398
46. S. Seeley, L. Covic, S.L. Jacques, J. Sudmeier, J.D. Baleja, and A. Kuliopulos Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding Chem. Biol. 10 2003 1033 1041 (Pubitemid 37496433)
47. P. Ventosa-Andrés, A.M. Valdivielso, I. Pappos, M.T. García-López, N.E. Tsopanoglou, and R. Herranz Design, synthesis and biological evaluation of new peptide-based ureas and thioureas as potential antagonists of the thrombin receptor PAR1 Eur. J. Med. Chem. 58 2012 98 111
48. S. Herrero, M.T. García-López, M. Latorre, E. Cenarruzabeitia, J. Del Río, and R. Herranz 2-Oxopiperazine-based gamma-turn conformationally constrained peptides: synthesis of CCK-4 analogues J. Org. Chem. 67 2002 3866 3873 (Pubitemid 34564001)
49. A.M. Valdivielso, P. Ventosa-Andrés, M.T. García- López, R. Herranz, and M. Gutiérrez-Rodríguez Synthesis and regioselective functionalization of piperazin-2-ones based on Phe-Gly pseudodipeptides Eur. J. Org. Chem. 2013 2013 155 161
50. C. Knox, V. Law, T. Jewison, P. Liu, S. Ly, A. Frolkis, A. Pon, K. Banco, C. Mak, V. Neveu, Y. Djoumbou, R. Eisner, A.C. Guo, and D.S. Wishart DrugBank 3.0: a comprehensive resource for 'omics' research on drugs Nucleic Acids Res. 39 2011 D1035 D1041
51. R. Herranz, M.L. Suárez-Gea, S. Vinuesa, and M.T. García-López Studies on the synthesis of cyanomethyleneamino pseudopeptides J. Org. Chem. 58 1993 5186 5191
52. Y. Yamamoto, and S. Kojima Synthesis and chemistry of guanidine derivatives S. Patai, Z. Rappoport, The Chemistry of Amidines and Imidates 1991 John Wiley & Sons, Ltd. Chichester 485 526
53. K. Kanamori, and J.D. Roberts A nitrogen-15 NMR study of the barriers to isomerization about guanidinium and guanidino carbon-nitrogen bonds in l-arginine J. Am. Chem. Soc. 105 1983 4698 4701 (Pubitemid 13571448)
54. W.X. Zhang, M. Nishiura, and Z. Hou Catalytic addition of amine N-H bonds to carbodiimides by half-sandwich rare-earth metal complexes: efficient synthesis of substituted guanidines through amine protonolysis of rare-earth metal guanidinates Chem. Eur. J. 13 2007 4037 4051 (Pubitemid 46927874)
55. J.-A. Fehrentz, and B. Castro An efficient synthesis of optically active α-(t-butoxycarbonylamino)-aldehydes from α-amino acids Synthesis 1983 1983 676 678
56. E. Ko, J. Liu, L.M. Perez, G. Lu, A. Schaefer, and K. Burgess Universal peptidomimetics J. Am. Chem. Soc. 133 2010 462 477
57. M. Amatore, T.D. Beeson, S.P. Brown, and D.W.C. MacMillan Enantioselective linchpin catalysis by SOMO catalysis: an approach to the asymmetric α-chlorination of aldehydes and terminal epoxide formation Angew. Chem. Int. Ed. 48 2009 5121 5124
58. S. Rendler, and D.W.C. MacMillan Enantioselective polyene cyclization via organo-SOMO catalysis J. Am. Chem. Soc. 132 2010 5027 5029
59. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112 (Pubitemid 20213250)
60. R.H. Shoemaker The NCI60 human tumour cell line anticancer drug screen Nat. Rev. Cancer 6 2006 813 823 (Pubitemid 44450469)